Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

77 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer.
Gadgeel S, Rodríguez-Abreu D, Speranza G, Esteban E, Felip E, Dómine M, Hui R, Hochmair MJ, Clingan P, Powell SF, Cheng SY, Bischoff HG, Peled N, Grossi F, Jennens RR, Reck M, Garon EB, Novello S, Rubio-Viqueira B, Boyer M, Kurata T, Gray JE, Yang J, Bas T, Pietanza MC, Garassino MC. Gadgeel S, et al. Among authors: bischoff hg. J Clin Oncol. 2020 May 10;38(14):1505-1517. doi: 10.1200/JCO.19.03136. Epub 2020 Mar 9. J Clin Oncol. 2020. PMID: 32150489 Free article. Clinical Trial.
Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial.
Douillard JY, Shepherd FA, Hirsh V, Mok T, Socinski MA, Gervais R, Liao ML, Bischoff H, Reck M, Sellers MV, Watkins CL, Speake G, Armour AA, Kim ES. Douillard JY, et al. J Clin Oncol. 2010 Feb 10;28(5):744-52. doi: 10.1200/JCO.2009.24.3030. Epub 2009 Dec 28. J Clin Oncol. 2010. PMID: 20038723 Clinical Trial.
Comparison of treatment costs of grade 3/4 adverse events associated with erlotinib or pemetrexed maintenance therapy for patients with advanced non-small-cell lung cancer (NSCLC) in Germany, France, Italy, and Spain.
Banz K, Bischoff H, Brunner M, Chouaid C, de Castro Carpeño J, de Marinis F, Grossi F, Vergnenègre A, Walzer S. Banz K, et al. Lung Cancer. 2011 Dec;74(3):529-34. doi: 10.1016/j.lungcan.2011.04.010. Epub 2011 May 17. Lung Cancer. 2011. PMID: 21592611
Characteristics and outcome of patients with second primary lung cancer.
Reinmuth N, Stumpf A, Stumpf P, Muley T, Kobinger S, Hoffmann H, Herth FJ, Schnabel PA, Warth A, Bischoff H, Thomas M. Reinmuth N, et al. Eur Respir J. 2013 Dec;42(6):1668-76. doi: 10.1183/09031936.00022512. Epub 2012 Oct 11. Eur Respir J. 2013. PMID: 23060634 Free article.
Characteristics of lung cancer after a previous malignancy.
Reinmuth N, Stumpf P, Stumpf A, Muley T, Kobinger S, Hoffmann H, Herth FJ, Schnabel PA, Bischoff H, Thomas M. Reinmuth N, et al. Respir Med. 2014 Jun;108(6):910-7. doi: 10.1016/j.rmed.2014.02.015. Epub 2014 Mar 5. Respir Med. 2014. PMID: 24650574 Free article.
EML4-ALK fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK+ non-small cell lung cancer.
Christopoulos P, Endris V, Bozorgmehr F, Elsayed M, Kirchner M, Ristau J, Buchhalter I, Penzel R, Herth FJ, Heussel CP, Eichhorn M, Muley T, Meister M, Fischer JR, Rieken S, Warth A, Bischoff H, Schirmacher P, Stenzinger A, Thomas M. Christopoulos P, et al. Int J Cancer. 2018 Jun 15;142(12):2589-2598. doi: 10.1002/ijc.31275. Epub 2018 Jan 24. Int J Cancer. 2018. PMID: 29363116 Free article.
77 results